Abstract 1581P
Background
Surgery with perioperative chemotherapy has been standard of care in patients with locally advanced gastric and gastroesophageal junction (GEJ) cancer since FLOT4-AIO trial. However, less than half of patients complete all adjuvant cycles. We studied total neoadjuvant chemotherapy with FOLFIRINOX regimen followed by surgery in this setting.
Methods
We conducted non-randomized, open-label, single-center phase II study in 119 patients with locally advanced resectable gastric and GEJ cancer. Sixty patients were enrolled to received 8 cycles of FOLFIRINOX preoperatively. This prospective cohort was compared to the retrospective cohort (n = 59), that received standard perioperative FLOT regimen (4 cycles before and 4 cycles after surgery). The primary endpoint was disease-free survival (DFS). Secondary endpoints were safety profile and pathological complete response rate (pCR).
Results
In the FOLFIRINOX and FLOT groups 78,6% and 77,8% of patients completed all planned cycles and underwent surgery, respectively. Dose reductions and drug withdrawal rates were higher in the FLOT group. More patients achieved pCR and near-pCR in the FLOT group by three different tumor regression grading systems (TRG 1a/b by Becker, 1/2 by Mandart, and 3/4 by Lavnikova): 47,7%, 40,5%, and 35,7% in the FLOT group and 25%, 27,3%, and 29,6% in the FOLFIRINOX group, respectively, though statistically insignificant. pCR or partial pathological response by any of TRG systems did not predict one-year DFS regardless of the treatment regimen. One-year DFS was numerically higher in the FOLFIRINOX group - 90,4% vs 67,5 % in the FLOT group (hazard ratio [HR] 0,65, 95% CI 0,29 – 1,45, p=0,29). The risk of recurrence in the FOLFIRINOX group was lower than in the FLOT group (odds ratio [OR] 0,40, 95% CI 0,16-0,97, p=0,047). Regional lymph node involvement (ypN2), lymphatic, vascular and perineural invasion negatively affected DFS (p=0,046; p=0,014; p=0,0021; p=0,04, respectively).
Conclusions
The total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with locally advanced gastric and GEJ cancer demonstrated comparable to the perioperative FLOT one-year DFS rate regardless of pCR and manageable safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22